Biotechnology
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces thatthe United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold ki...
Telix Successfully Prices A$650 Million Convertible Bonds
MELBOURNE, Australia, July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully pricedA$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as "convertible bond...
Telix Announces A$600 Million Convertible Bonds Offering
MELBOURNE, Australia, July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering ofA$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as "convertible bonds" (Convertible Bonds)...
SND Introduces Revolutionary Moderated Drinking Treatment Program
TOKYO, July 23, 2024 /PRNewswire/ -- SND Incorporated (Headquarters: Chiyoda-ku, Tokyo; CEO: Takayuki Hiiragi) is proud to announce the launch of its groundbreaking Moderated Drinking Treatment Program for alcohol dependency. This innovative approach offers a compassionate alternative to tradition...
QDX Announces Collaboration with Prelude Therapeutics on Novel Oncology Programs
SINGAPORE, July 23, 2024 /PRNewswire/ -- QDX
DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease
* Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trials * Achieves alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Phase III program SALT LAKE CITY, July 23, 2024 /PRNewswire/ -- DiscGenics, Inc., a privately held, l...
Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency
SHANGHAI, July 22, 2024 /PRNewswire/ -- The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is an innovativ...
Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
* Obese and overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0...
Join Hands for a Brighter Future!2024 Tianjin Binhai New Area Innovation and Entrepreneurship Competition Overseas Event (Hong Kong SAR Division) Concluded Successfully
HONG KONG, July 22, 2024 /PRNewswire/ -- On July 17, 2024, the Hong Kong SAR division of the 2024 Tianjin Binhai New Area Innovation and Entrepreneurship Competition concluded successfully. Top scientists, business leaders, government officials, and elite entrepreneurs from around the world gathe...
Duke-NUS launches LIVE Ventures, a S$20 million incubator to accelerate research commercialisation
* New incubator aims to tap industry experts to bridge the knowledge and funding gap to enhance bench-to-bedside success * LIVE Ventures provides up to $500,000 for high-potential academic research projects SINGAPORE, July 22, 2024 /PRNewswire/ -- Duke-NUS Medical School today launched LIVE V...
Agilent Introduces New ProteoAnalyzer at Singapore Cell and Gene Therapy Pan Asia Summit
SINGAPORE, July 22, 2024 /PRNewswire/ -- Agilent Technologies Inc.
Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis
SHANGHAI, July 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first Chinese patient has be...
Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
SAN FRANCISCO and SUZHOU, China, July 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...
DX&VX is on Track and Accelerating the Development of Oral Obesity Treatment
* Confirmation of effects compared to global late-stage clinical trials * Accelerating the development of obesity treatment through early licensing out, global joint clinical trials, research funding investment, etc. SEOUL, South Korea, July 18, 2024 /PRNewswire/ -- DX&VX, which is gaining att...
BioWorld by Clarivate Celebrates Nine Wins at 2024 APEX Awards
Recognized for excellence in writing, news, mental health, financial/investment and economics categories LONDON, July 18, 2024 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has been honored with nine2024 APEX Awards fo...
Getinge Interim Report April-June 2024: Higher sales, stronger margins and product launches with significant added value for customers
GOTHENBURG, Sweden, July 18, 2024 /PRNewswire/ -- "Net sales increased by 15.7% in the second quarter, of which the organic increase was 8.9%," says Mattias Perjos, President & CEO at Getinge. "The operating margin improved compared with last year due to strong sales and a positive product mix, w...
Research Identifies Blind Spots That Affect Quality of Life Among People with HIV in Singapore
Dedicated mobile app to encourage proactive management of physical health, mental well-being and chronic disease SINGAPORE, July 18, 2024 /PRNewswire/ -- With the advancements in medical sciences, there is now very little difference between the life expectancy of people with HIV (PWH) and the ge...
PairX Bio Clinches Coveted Amgen Golden Ticket Award, as NSG BioLabs Deepens Efforts with Partners CapitaLand and Amgen to Boost Singapore's Biotech Ecosystem with Fourth Site and Extended Awards Programme
* The Amgen Golden Ticket Award, now in its third year, showcases Amgen's and NSG BioLabs' efforts to support high-growth startups in a nurturing ecosystem, with a doubling of applicants compared to last year * Amgen and NSG BioLabs extended the Golden Ticket partnership for another three y...
China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products
SHENZHEN, China, July 18, 2024 /PRNewswire/ -- The 90th China International Medical Equipment Fair (CMEF) is set to take place inShenzhen from October 12th to 15th, 2024. With an expected attendance of over 200,000 visitors from more than 150 countries, the exhibition is poised to be a global sho...
Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration
SHANGHAI, July 18, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced thatChina's National Medical Products ...
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 269 media titles]
2026-01-01 10:00CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00